Literature DB >> 21909031

Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy.

Lynne M Mofenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21909031     DOI： 10.1097/QAI.0b013e318235517e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  10 in total

1.  HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.

Authors:  Nicole A Doria-Rose; Mark K Louder; Zhongjia Yang; Sijy O'Dell; Martha Nason; Stephen D Schmidt; Krisha McKee; Michael S Seaman; Robert T Bailer; John R Mascola
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

Review 2.  Immunotherapies to prevent mother-to-child transmission of HIV.

Authors:  Mark D Hicar
Journal:  Curr HIV Res       Date:  2013-03       Impact factor: 1.581

Review 3.  Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis.

Authors:  Stacey A Hurst; Kristie E Appelgren; Athena P Kourtis
Journal:  Expert Rev Anti Infect Ther       Date:  2015-02       Impact factor: 5.091

4.  Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.

Authors:  Kenneth Kintu; Philip Andrew; Philippa Musoke; Paul Richardson; Brenda Asiimwe-Kateera; Teopista Nakyanzi; Lei Wang; Mary Glenn Fowler; Lynda Emel; San-San Ou; Lynn Baglyos; Sanjay Gurunathan; Sheryl Zwerski; Jay Brooks Jackson; Laura Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

5.  Neutralization of HIV by milk expressed antibody.

Authors:  Xiaocong Yu; Daniel Pollock; Mark Duval; Christopher Lewis; Kristin Joseph; Harry Meade; Lisa Cavacini
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

6.  HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.

Authors:  Sallie R Permar; Genevieve G Fouda; Erin P McGuire; Youyi Fong; Christopher Toote; Coleen K Cunningham; Elizabeth J McFarland; William Borkowsky; Susan Barnett; Hannah L Itell; Amit Kumar; Glenda Gray; M Julianna McElrath; Georgia D Tomaras
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

7.  Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.

Authors:  Jos Lommerse; Diana Clarke; Thomas Kerbusch; Henri Merdjan; Han Witjes; Hedy Teppler; Mark Mirochnick; Edward P Acosta; Larissa Wenning; Sharon Nachman; Anne Chain
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-07-10

8.  Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.

Authors:  Pontiano Kaleebu; Harr Freeya Njai; Lei Wang; Norman Jones; Isaac Ssewanyana; Paul Richardson; Kenneth Kintu; Lynda Emel; Philippa Musoke; Mary Glenn Fowler; San-San Ou; J Brooks Jackson; Laura Guay; Philip Andrew; Lynn Baglyos; Huyen Cao
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

Review 9.  The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Authors:  Martine Braibant; Francis Barin
Journal:  Retrovirology       Date:  2013-10-07       Impact factor: 4.602

10.  Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Authors:  Ann J Hessell; J Pablo Jaworski; Erin Epson; Kenta Matsuda; Shilpi Pandey; Christoph Kahl; Jason Reed; William F Sutton; Katherine B Hammond; Tracy A Cheever; Philip T Barnette; Alfred W Legasse; Shannon Planer; Jeffrey J Stanton; Amarendra Pegu; Xuejun Chen; Keyun Wang; Don Siess; David Burke; Byung S Park; Michael K Axthelm; Anne Lewis; Vanessa M Hirsch; Barney S Graham; John R Mascola; Jonah B Sacha; Nancy L Haigwood
Journal:  Nat Med       Date:  2016-03-21       Impact factor: 53.440
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.